Mineralocorticoid receptor antagonist spironolactone improves left ventricular remodeling in patients with congestive heart failure and acute myocardial infarction

Folia Pharmacologica Japonica

Volumn 124, Issue 2, 2004, Pages 90-100

  Tsutamoto, Takayoshi ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Aldosterone; Congestive heart failure; Left ventricular remodeling; Spironolactone

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; EPLERENONE; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; SPIRONOLACTONE;

ACUTE HEART INFARCTION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HEART FAILURE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART VENTRICLE REMODELING; HEMODYNAMIC PARAMETERS; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ALDOSTERONE ANTAGONISTS; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; SPIRONOLACTONE; VENTRICULAR REMODELING;

EID: 4143061290     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.124.90     Document Type: Review

References (19)

1. Weber KT, Janicki JS, Pick R, Capasso J, Anversa P. Myocardial fibrosis and pathologic hypertrophy in the rat with renovascular hypertension. Am J Cardiol. 1990;65:1G-7G.
2. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin angiotensin aldosterone system. Circulation. 1991;83:1849-1865.
3. Struthers AD. Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur Heart J. 1995;16 Suppl N:103-107.
4. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on mortality and morbidity in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
5. Scott BA, Lawrence B, Nguyen HH, Meyer WJ 3rd. Aldosterone and dexamethasone binding in human arterial smooth muscle cells. J Hypertens. 1987;5:739-744.
6. Lombes M, Alfaidy N, Eugene E, Lessana A, Farman N, Bonvalet JP. Prerequisite for cardiac aldosterone action: mineralocorticoid receptor and 11β-hydroxysteroid dehydrogenase in the human heart. Circulation. 1995;92:175-182.
7. Zennaro MC, Farman N, Bonvalet JP, Lombes M. Tissue-specific expression of α- and β-messenger ribonucleic acid isoforms of the human mineralocorticoid receptor in normal and pathological states. J Clin Endocrinol Metab. 1997;82:1345-1352.
8. Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic JM, et al. Myocardial production of aldosterone and corticosterone in the rat. J Biol Chem. 1998;273:4883-4891.
9. Kayes-Wandover KM, White PC. Steroidogenic enzyme gene expression in the human heart. J Clin Endocrinol Metab. 2000;85:2519-2525.
10. Yoshimura M, Nakamura S, Ito T, Nakayama M, Harada E, Mizuno Y, et al. Expression of aldosterone synthase gene in failing human heart: quantitative analysis using modified real-time polymerase chain reaction. J Clin Endocrinol Metab. 2002;87:3936-3940.
11. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, et al. Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol. 2000;36:838-844.
12. Tsutamoto T, Wada A, Maeda K, Hayashi M, Tsutsui T, Ohnishi M, et al. Transcardiac gradient of aldosterone before and after spironolactone in patients with congestive heart failure. J Cardiovasc Pharmacol. 2002;41(Suppl.1):S19- S22.
13. Hayashi M, Tsutamoto T, Wada A, Maeda K, Mabuchi N, Tsutsui T, et al. Relationship between tumor necrosis factor a production and oxidative stress in the failing heart of patients with dilated cardiomyopathy. J Am Coll Cardiol. 2001;37:2086-2092.
14. Hayashi M, et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol. 2001;37:1820-1826.
15. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol. 2001;37:1228-1233.
16. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 1997;96:509-516.
17. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
18. Hayashi M, Tsutamoto T, Wada A, Tsutsui T, Ishii C, Ohno K, et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003;107:2559-2565.